Immunogen Q2 EPS $(0.02) Beats $(0.16) Estimate, Sales $83.15M Beat $42.84M Estimate
Portfolio Pulse from Benzinga Newsdesk
Immunogen reported Q2 earnings per share of $(0.02), beating the analyst consensus estimate of $(0.16) by 87.5%. The company also reported quarterly sales of $83.15 million, surpassing the analyst consensus estimate of $42.84 million by 94.10%. This represents a 487.16% increase over sales from the same period last year.
July 31, 2023 | 10:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunogen's Q2 earnings and sales significantly exceeded analyst estimates, indicating a strong financial performance.
Immunogen's better-than-expected Q2 results indicate a strong financial performance, which is likely to positively impact investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100